Overexpression of HER3 has been implicated in the progression of ovarian cancer and in the development of chemotherapy resistance, as it can compensate for or reactivate survival pathways when tumors are challenged with targeted therapies or cytotoxic drugs [25,28]. The gene discussed is ERBB3; the disease is ovarian cancer.